title: Ingestion of ferrous sulfate increases ferremia in patients with short bowel syndrome.
abstract: OBJECTIVE
  Because short bowel syndrome is associated with iron deficiency, the objective of the present study was to monitor ferremia after the ingestion of different iron compounds and doses in enterectomized patients.
  
  
  METHODS
  This was a randomized, double-blind, cross-over study conducted in 13 patients of both sexes in the metabolic unit of Hospital das Clínicas de Faculdade de Medicina de Ribeirão Preto-Universídade de São Paulo and was divided into two stages. Three different iron compounds, ferrous sulfate (FS), sodium iron ethylenediaminetetra-acetic acid (EDTA), and dehydrated cell fraction (DCF), were studied. The patients were randomly assigned to one of four groups receiving high-dose DCF (120mg) and low-dose DCF (5mg) and the two iron compounds. The subjects (n=7) receiving high-dose DCF participated in 2 test days. All patients receiving the physiologic dose (low-dose DCF, n=6) participated in 3 test days with a 1-mo interval between compounds. After an 8-h fast, blood samples were collected at 0.25, 0.5, 1, and 2h. Serum iron curve and the sum of the area under the curve were calculated and adjusted according to a mixed-effect linear model (P<0.05).
  
  
  RESULTS
  Serum FS levels were higher in the 120-mg group compared with the others (P<0.005). The mean areas under the curve for FS and EDTA at the doses of 120 and 5mg of elemental iron were 238, 224, 177, and 153 microg/dL, respectively. The mean area under the curve for DCF was 165 microg/dL, with no significant difference between groups.
  
  
  CONCLUSIONS
  Regardless of dose, FS was the compound that resulted in higher ferremia compared with the other doses and compounds.
authors.affiliation: Division of Clinical Nutrition, Department of Internal Medicine, Ribeirão Preto School of Medicine, São Paulo University Ribeirao Preto, Sao Paulo, Brazil. fabirainato@yahoo.com.br
authors.forename: Fabíola Rainato
authors.initials: FR
authors.lastname: Gabriel
authors.forename: Vivian M M
authors.initials: VM
authors.lastname: Suen
authors.forename: Julio Sergio
authors.initials: JS
authors.lastname: Marchini
authors.forename: José Eduardo
authors.initials: JE
authors.lastname: Dutra de Oliveira
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D001938:Brazil; D002458:Cell Fractionation; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004492:Edetic Acid / Q000494:pharmacology; D004912:Erythrocytes; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012778:Short Bowel Syndrome / Q000097:blood* / Q000601:surgery
chemical_list: D005296:Ferrous Compounds; C020748:ferrous sulfate; D004492:Edetic Acid; D007501:Iron